Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORGANON
NCT02935855Phase 4Completed
- Sponsor
- University of Pavia
- Start
- Sep 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dabigatran, apixaban, rivaroxaban and edoxaban in nonvalvular atrial fibrillation (NVAF) (4 arms), sponsored by University of Pavia. Primary endpoint: Efficacy on coagulation parameters at 12 months. Started Sep 2015; status: completed.
02
Drugs
dabigatranapixabanrivaroxabanedoxaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)
Beyond the preview
Go deeper on NCT02935855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935855.